Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

20
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
20
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC).

Systematic reviews·2026
Same author

Are we ready to predict progressive disease in juvenile systemic sclerosis?

Journal of scleroderma and related disorders·2026
Same author

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.

Journal of scleroderma and related disorders·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Expert review of clinical immunology·2026
Same author

Calcinosis Cutis and Delayed-Onset Myositis in a Case of Suspected Localized Scleroderma: A Diagnostic and Therapeutic Challenge.

Pediatric dermatology·2026

相关实验视频

Updated: Jul 23, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

在青少年局部性硬化症的全身疗法.

Ivan Foeldvari1, Edoardo Marrani2

  • 1Hamburger Zentrum Für Kinder- Und Jugendrheumatologie, Hamburg, Germany.

Expert review of clinical immunology
|July 18, 2023
PubMed
概括

早期治疗青少年局部性硬皮病 (JLS) 对于预防长期残疾至关重要. 本综述概述了疾病评估和治疗到目标的全身治疗计划,包括甲状腺素作为一线选择.

科学领域:

  • 儿科风湿病学 儿科风湿病学
  • 皮肤病学 皮肤病学
  • 自身免疫性结缔组织疾病

背景情况:

  • 青少年局部性硬化症 (JLS) 是一种罕见的儿童疾病,如果不治疗,会导致严重的发病率.
  • 在炎症阶段迅速干预至关重要,以防止永久性损伤和功能残疾.

研究的目的:

  • 审查JLS中评估疾病活动和损害的方法.
  • 提出基于治疗到目标的方法的系统治疗升级策略.
  • 确定不活性的疾病和药物停用的标准.

主要方法:

  • 讨论治疗监测的基线疾病活性评估.
  • 重点是评估皮肤外干扰.
  • 提出一个分层的全身治疗方法,优先考虑甲状腺素作为一线治疗.

主要成果:

  • 对于大多数JLS患者,建议进行全身治疗.
  • 甲托雷克萨特是首选的一线疾病修饰性抗风湿药物 (DMARD).
  • 对于甲状腺素不耐受或不反应的病例,需要制定治疗升级计划.

结论:

  • 及时对JLS进行评估和干预至关重要.
关键词:
自体脂肪移植自体脂肪移植雅克抑制剂的使用伤害的伤害的伤害的伤害.疾病修饰剂是疾病修饰剂.不活跃的疾病不活跃的疾病.局部性硬化皮肤病局部性硬化皮肤病莫菲亚 (Morphea) 是一个形象.结果结果结果结果.缓解缓解是一种缓解.

更多相关视频

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

7.8K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

相关实验视频

Last Updated: Jul 23, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

7.8K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
  • 对于管理JLS而言,一个结构化,治疗到目标的方法,以及潜在的升级至关重要.
  • 对预后标志物的进一步研究是必要的,以指导治疗决策.